ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
The NCL Foundation has opened the Rare-to-Common Neurodegeneration Impact Prize, a €200,000 research award supporting collaborative projects that connect CLN3 Batten disease research with more common neurodegenerative or age-related disorder
ERDERA will launch its Clinical Trial Call (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
